Precision Medicine in Oncology^®

Broader NGS Use in Oncology Hinges on Payers, Access, and Education

Using up-front, broadpanel genomic tests that include hundreds of genes can save money and, in some cases, improve outcomes compared with other diagnostic approaches, especially in lung cancer but also increasingly in breast, colorectal, skin, and other...
Read More >>

cfDNA Assay Emerges as Viable Option for MSI Detection

Expert Advocates Universal Genetic Testing in Breast Cancer

CMS Should Broaden Coverage for Germline Mutation Testing

Larotrectinib Likely to Get EU Nod for NTRK+ Tumors

Turning to Broad Sequencing Panels for Targeted Therapy in Advanced NSCLC

View More Stories >>

View Conference Coverage

Charlotte Plasma Cell Disorder Congress

State of the Science Summit on Breast Cancer in Long Island

2019 International Lung Cancer Congress

2019 State of the Science Summit on Genitourinary Cancers in Jacksonville

2019 State of the Science Summit on Hematologic Malignancies in Pittsburgh

Dr. Papadimitrakopoulou on Implications of the NILE Trial in NSCLC

Dr. Papadimitrakopoulou on Benefits of Liquid Biopsy Versus Standard Tissue in Lung Cancer

Dr. Papadimitrakopoulou on Distinguishing Features of the Guardant360 Assay in Lung Cancer

Dr. Papadimitrakopoulou on the Utility of Liquid Biopsies in NSCLC

Dr. Chavez Mac Gregor on Chemotherapy in Node-Positive HR+/HER2- Breast Cancer

Dr. Strickler on Genomic Variants Detected by Liquid Biopsies in GI Cancers

OncLive houses thousands of videos that provide updates and information.
See more Videos

ROS1-Rearranged NSCLC

Managing CNS Disease in ALK-Rearranged NSCLC

ALK-Rearranged Lung Cancer

Novel EGFR Exon 20 Directed Therapies for NSCLC

RELAY: Erlotinib with Ramucirumab for EGFR+ NSCLC

Novel EGFR Inhibitor Combinations for NSCLC

OncLive houses thousands of videos that provide updates and information.
See more Videos

Considering Available Data for Entrectinib

TRK Inhibition: Personal Experience With Larotrectinib

Larotrectinib for NTRK Fusions: Patient Selection

Larotrectinib: The First FDA-Approved TRK Inhibitor

Emerging Approaches for BRAF-Mutant Metastatic Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Program

Treatment of Advanced Head & Neck Squamous Cell Carcinoma

Ezra Cohen, MD; Robert Ferris, MD, PhD, FACS; and Jared Weiss, MD, provide a comprehensive overview of diagnosis and treatment of advanced head and neck squamous cell carcinoma (HNSCC), including multidisciplinary care and emerging evidence surrounding novel therapies. Treatment approaches to HPV-positive and HPV-negative tumors are explored.